| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7691411 | INSTITUT BIOCHIMIQUE | Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
Mar, 2024
(5 months from now) | |
| US7723390 | INSTITUT BIOCHIMIQUE | Pharmaceutical formulations for thyroid hormones |
Mar, 2024
(5 months from now) | |
Tirosint is owned by Institut Biochimique.
Tirosint contains Levothyroxine Sodium.
Tirosint has a total of 2 drug patents out of which 0 drug patents have expired.
Tirosint was authorised for market use on 13 October, 2006.
Tirosint is available in capsule;oral dosage forms.
The generics of Tirosint are possible to be released after 14 March, 2024.
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 13 October, 2006
Treatment: NA
Dosage: CAPSULE;ORAL
How can I launch a generic of TIROSINT before it's drug patent expiration?
More Information on Dosage
TIROSINT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic